JP2018530592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530592A5 JP2018530592A5 JP2018519437A JP2018519437A JP2018530592A5 JP 2018530592 A5 JP2018530592 A5 JP 2018530592A5 JP 2018519437 A JP2018519437 A JP 2018519437A JP 2018519437 A JP2018519437 A JP 2018519437A JP 2018530592 A5 JP2018530592 A5 JP 2018530592A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sglt
- patient
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010068836 Metabolic myopathy Diseases 0.000 claims 4
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 3
- 208000007345 glycogen storage disease Diseases 0.000 claims 3
- 229920002527 Glycogen Polymers 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 1
- 229960003345 empagliflozin Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 208000025973 glycogen metabolism disease Diseases 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242030P | 2015-10-15 | 2015-10-15 | |
| US62/242,030 | 2015-10-15 | ||
| US201662347747P | 2016-06-09 | 2016-06-09 | |
| US62/347,747 | 2016-06-09 | ||
| PCT/EP2016/074601 WO2017064193A1 (en) | 2015-10-15 | 2016-10-13 | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530592A JP2018530592A (ja) | 2018-10-18 |
| JP2018530592A5 true JP2018530592A5 (enExample) | 2019-11-21 |
Family
ID=57130398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519437A Pending JP2018530592A (ja) | 2015-10-15 | 2016-10-13 | 代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US20170106009A1 (enExample) |
| EP (1) | EP3362055B1 (enExample) |
| JP (1) | JP2018530592A (enExample) |
| WO (1) | WO2017064193A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| AP2011005794A0 (en) | 2009-02-13 | 2011-08-31 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof. |
| BR112012007085B8 (pt) | 2009-09-30 | 2021-05-25 | Boehringer Ingelheim Int | processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HRP20190101T1 (hr) | 2013-04-05 | 2019-03-08 | Boehringer Ingelheim International Gmbh | Terapeutske uporabe empagliflozina |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HUE058731T2 (hu) | 2013-04-18 | 2022-09-28 | Boehringer Ingelheim Int | Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai |
| EP3362055B1 (en) | 2015-10-15 | 2023-01-18 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
| MX2019005435A (es) | 2016-11-10 | 2019-07-10 | Boehringer Ingelheim Int | Composicion farmaceutica, metodos para tratamiento y sus usos. |
| CN111110949B (zh) * | 2018-11-01 | 2021-07-09 | 上海市第六人民医院 | 胰岛素注射量确定方法及装置、计算机存储介质及设备 |
| CN115515435A (zh) * | 2020-02-11 | 2022-12-23 | 沃尔夫森医疗中心 | 有效治疗溃疡性结肠炎的方法 |
| EP4341401A1 (en) * | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| EP1364958B1 (en) | 2001-02-27 | 2010-09-08 | Kissei Pharmaceutical Co., Ltd. | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
| ES2387881T3 (es) | 2004-03-16 | 2012-10-03 | Boehringer Ingelheim International Gmbh | Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| CA2587639A1 (en) | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DE602006017566D1 (de) | 2005-08-30 | 2010-11-25 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| RU2008113050A (ru) | 2005-09-08 | 2009-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| EA200801773A1 (ru) | 2006-02-15 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| TW200829258A (en) | 2006-11-06 | 2008-07-16 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| EP3037095A3 (en) | 2006-11-09 | 2016-11-16 | Boehringer Ingelheim International GmbH | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| CN101638423B (zh) | 2008-07-29 | 2012-09-05 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 根皮苷衍生物及其制备方法和用途 |
| WO2010049678A2 (en) * | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| AU2014200258B2 (en) | 2009-02-13 | 2016-05-12 | Boehringer Ingelheim International Gmbh | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
| FI2395968T3 (fi) | 2009-02-13 | 2024-02-27 | Boehringer Ingelheim Int | Glukopyranosylidifenylimetaanijohdannaisia sisältävä farmaseuttinen koostumus, niiden farmaseuttinen annostusmuoto, niiden valmistusmenetelmä ja niiden käyttö potilaan glukemiasäädön parantamiseksi |
| UA106365C2 (ru) | 2009-02-13 | 2014-08-26 | Берингер Ингельхайм Интернациональ Гмбх | Способ улучшения гликемического контроля и способ снижения жира в организме с применением ингибитора sglt-2 |
| PL2483286T3 (pl) | 2009-09-30 | 2017-04-28 | Boehringer Ingelheim International Gmbh | Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US10688116B2 (en) | 2014-04-01 | 2020-06-23 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| KR102539788B1 (ko) | 2014-09-25 | 2023-06-07 | 베링거잉겔하임베트메디카게엠베하 | 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료 |
| EP3362055B1 (en) | 2015-10-15 | 2023-01-18 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
-
2016
- 2016-10-13 EP EP16781135.5A patent/EP3362055B1/en not_active Revoked
- 2016-10-13 WO PCT/EP2016/074601 patent/WO2017064193A1/en not_active Ceased
- 2016-10-13 JP JP2018519437A patent/JP2018530592A/ja active Pending
- 2016-10-13 US US15/292,234 patent/US20170106009A1/en not_active Abandoned
-
2019
- 2019-03-14 US US16/353,000 patent/US20190209596A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,091 patent/US20200397809A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/809,618 patent/US20220323473A1/en not_active Abandoned
-
2023
- 2023-11-10 US US18/506,167 patent/US20240082283A1/en not_active Abandoned